These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9151153)
21. Platelet-activating protamine-heparin-antibodies lead to higher protamine demand in patients undergoing cardiac surgery. Grieshaber P; Bakchoul T; Wilhelm J; Wagner A; Wollbrück M; Böning A; Sachs U J Thorac Cardiovasc Surg; 2015 Oct; 150(4):967-73.e1. PubMed ID: 26298870 [TBL] [Abstract][Full Text] [Related]
22. A novel protamine variant reversal of heparin anticoagulation in human blood in vitro. Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Stoneham MD; Doyle AR; Zelenock GB; Jacobs LA; Shanley CJ; TenCate VM; Stanley JC J Vasc Surg; 1997 Dec; 26(6):1043-8. PubMed ID: 9423721 [TBL] [Abstract][Full Text] [Related]
23. A filter device for the prevention of both heparin- and protamine-induced complications associated with extracorporeal therapy. Yang VC; Teng CL; Kim JS Biomed Instrum Technol; 1990; 24(6):433-9. PubMed ID: 2261582 [TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study. Zwischenberger JB; Tao W; Deyo DJ; Vertrees RA; Alpard SK; Shulman G Ann Thorac Surg; 2001 Jan; 71(1):270-7. PubMed ID: 11216760 [TBL] [Abstract][Full Text] [Related]
25. Protamine pretreatment attenuation of hemodynamic and hematologic effects of heparin-protamine interaction. A prospective randomized study in human beings undergoing aortic reconstructive surgery. Wakefield TW; Hantler CB; Lindblad B; Whitehouse WM; Stanley JC J Vasc Surg; 1986 Jun; 3(6):885-9. PubMed ID: 3712636 [TBL] [Abstract][Full Text] [Related]
26. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. Demma L; Levy JH Anesth Analg; 2012 Dec; 115(6):1273-8. PubMed ID: 22859690 [TBL] [Abstract][Full Text] [Related]
27. Extracorporeal immunoadsorption in heparin- and protamine-induced thrombocytopaenia prior to cardiac surgery. Füreder L; Böhmig GA; Schaefer AK; Steinlechner B Eur J Cardiothorac Surg; 2019 Jul; 56(1):206-207. PubMed ID: 30541064 [TBL] [Abstract][Full Text] [Related]
28. Effect of methylprednisolone on complement activation during heparin neutralization. Loubser PG J Cardiovasc Pharmacol; 1997 Jan; 29(1):23-7. PubMed ID: 9007666 [TBL] [Abstract][Full Text] [Related]
29. Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention. Patel AA; White CM; Coleman CI Conn Med; 2007 Feb; 71(2):93-5. PubMed ID: 17393902 [No Abstract] [Full Text] [Related]
30. Strategies for improving the functionality of an affinity bioreactor. Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511 [TBL] [Abstract][Full Text] [Related]
31. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. Dyke CM; Smedira NG; Koster A; Aronson S; McCarthy HL; Kirshner R; Lincoff AM; Spiess BD J Thorac Cardiovasc Surg; 2006 Mar; 131(3):533-9. PubMed ID: 16515902 [TBL] [Abstract][Full Text] [Related]
32. The heparin-protamine interaction. A review. Carr JA; Silverman N J Cardiovasc Surg (Torino); 1999 Oct; 40(5):659-66. PubMed ID: 10596998 [TBL] [Abstract][Full Text] [Related]
33. Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralization of heparin with protamine in awake sheep are infusion rate-dependent. Morel DR; Costabella PM; Pittet JF Anesthesiology; 1990 Sep; 73(3):415-24. PubMed ID: 2098007 [TBL] [Abstract][Full Text] [Related]
34. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770 [TBL] [Abstract][Full Text] [Related]
35. Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass. Gruenwald CE; Manlhiot C; Chan AK; Crawford-Lean L; Foreman C; Holtby HM; Van Arsdell GS; Richards R; Moriarty H; McCrindle BW J Am Coll Cardiol; 2010 Nov; 56(22):1794-802. PubMed ID: 21087706 [TBL] [Abstract][Full Text] [Related]
37. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568 [TBL] [Abstract][Full Text] [Related]
38. Activation of the clotting system: heparin-coated versus non coated systems for extracorporeal circulation. Urlesberger B; Zobel G; Rödl S; Dacar D; Friehs I; Leschnik B; Muntean W Int J Artif Organs; 1997 Dec; 20(12):708-12. PubMed ID: 9506788 [TBL] [Abstract][Full Text] [Related]
39. Platelet damage by protamine and the protective effect of prostacyclin: an experimental study in dogs. Velders AJ; Wildevuur CR Ann Thorac Surg; 1986 Aug; 42(2):168-71. PubMed ID: 3527093 [TBL] [Abstract][Full Text] [Related]
40. Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass. Miles LF; Marchiori P; Falter F Perfusion; 2017 Sep; 32(6):481-488. PubMed ID: 28820026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]